home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

265 rows where filing_period = "third_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 265 ✖

filing_year 1

  • 2017 · 265 ✖

filing_period 1

  • third_quarter · 265 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2017836 ROSE LAW FIRM, A PROFESSIONAL ASSOCIATION 286175f5-0489-42b0-b900-71d2aa0838a3 3T ROSE LAW FIRM, A PROFESSIONAL ASSOCIATION 78870 THE INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS 2017 third_quarter PHA Legislative efforts related to the implementation of the Food, Drug and Cosmetic Act, and the Drug Quality and Security Act (P.L 113-54). Issues related to reimbursement of compounded medications and recommended changes to the Social Security Act; drug pricing (no specific bills). Pharmacy inspection issues and concerns (no specific bills). Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 1 2017-08-11T09:16:31.547000-04:00
2018934 RED+BLUE STRATEGIES 8ac0c2fe-c42a-4d7c-bdf3-adcffac49bc2 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2017 third_quarter PHA Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-09-27T16:38:57.697000-04:00
2019393 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING c22efdea-f44c-41e4-8edc-c49a6257ee26 Q3 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2017 third_quarter PHA Compounding of radiopharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   10000 0 0 2017-10-03T11:32:14.850000-04:00
2019595 AMERICAN COLLEGE OF CLINICAL PHARMACY 90ddca98-51a5-4825-bc66-f73876dde068 Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2017 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128375 0 0 2017-10-04T09:57:51.917000-04:00
2020085 RED+BLUE STRATEGIES 5fb896d7-47fa-4325-b2ab-eacdf7bfbed8 Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2017 third_quarter PHA S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-05T15:57:20.950000-04:00
2020352 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM c3da4cb7-9edb-494a-8f67-f76d7fd32f07 Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2017 third_quarter PHA Graham-Cassidy-Heller HR 1628. Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HOUSE OF REPRESENTATIVES,SENATE   15335 0 0 2017-10-06T12:50:59.697000-04:00
2020457 PARRY, ROMANI, DECONCINI & SYMMS 9d1a9d70-4c30-4e42-a71d-98aa67fd7427 Q3 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2017-10-06T15:34:34.887000-04:00
2020924 HOLLAND & KNIGHT LLP 74e70921-0b55-4f83-8721-7cad75d3ff48 Q3 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2017 third_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2017-10-09T15:40:15.367000-04:00
2020927 HOLLAND & KNIGHT LLP 8a5a8ae3-96d7-483b-85f3-3ee8ce814094 Q3 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2017 third_quarter PHA Advocating for policy to ensure patient access to pain relief.   50000   0 0 2017-10-09T15:45:18.880000-04:00
2021164 RED+BLUE STRATEGIES 7b10e64d-c25d-4541-b54c-d45115628e3e Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2017 third_quarter PHA S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. Issues related to the price of prescription medications in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-10T11:26:11.380000-04:00
2021266 RED+BLUE STRATEGIES 6f7a834f-dc4b-45e1-9508-361f2ac6384c Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2017 third_quarter PHA S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-10T12:09:47.367000-04:00
2021278 POLITICAL CAPITAL, LLC 7a40af5a-bba6-4b2f-bfb5-7b090109e016 Q3 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2017 third_quarter PHA DQSA Oversight HR 2871 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-10-10T12:16:58.053000-04:00
2021749 ACG ADVOCACY f3f9fc2f-f4ae-4f7c-964a-c48755b57863 Q3 ACG ADVOCACY 2057 WALGREEN CO. 2017 third_quarter PHA Competition Policy Issues. HOUSE OF REPRESENTATIVES,SENATE,White House Office 180000   0 0 2017-10-11T10:31:22.690000-04:00
2021752 KATE MOSS f72ebd00-7175-4634-b7a8-c4c3c97a6c00 Q3 KATE MOSS 25988 CVS HEALTH 2017 third_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-10-11T10:32:28.457000-04:00
2022086 RED+BLUE STRATEGIES 799bc279-5317-43c5-9e33-39a872ff0451 Q3 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2017 third_quarter PHA Issues related to curbing the abuse of opioids in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-11T14:39:58.013000-04:00
2022107 PRINTING INDUSTRIES OF AMERICA, INC. 51e5d953-c729-49df-ad6c-01a39f3fadb2 Q3 PRINTING INDUSTRIES OF AMERICA, INC. 32203 PRINTING INDUSTRIES OF AMERICA INC 2017 third_quarter PHA Printed pharmaceutical literature/labeling issues. Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS)   80500 0 0 2017-10-11T14:51:08.997000-04:00
2022132 NELSON MULLINS RILEY & SCARBOROUGH cc1a9373-489a-4fef-981a-b3571b037362 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2017 third_quarter PHA Issues related to 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-10-11T15:09:23.333000-04:00
2022299 INDEPENDENT PHARMACY COOPERATIVE cb2c8647-eba7-461e-b11c-412e55cb9ec3 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2017 third_quarter PHA Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Support H.R. 2871 the "Preserving Patient Access to Compounded Medications Act of 2017 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2017-10-11T19:03:04.707000-04:00
2022379 NELSON MULLINS RILEY & SCARBOROUGH 042d0564-737f-4c9b-8742-d316a1495195 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2017 third_quarter PHA Issues related to the 340B Drug Pricing Program and biomedical research HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-10-12T09:40:14.140000-04:00
2022583 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) ae17d79d-8058-4b32-bbec-b8f4cac5afe4 Q3 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2017 third_quarter PHA Government Relations Services including developing strategies to achieve legislative goals HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-12T11:23:17.987000-04:00
2022888 MR. VINCENT A. PANVINI 77bf5b20-efe5-4b13-adbc-ef0bf89821c0 Q3 MR. VINCENT A. PANVINI 401008845 PHRMA 2017 third_quarter PHA Illegal Pharmaceutical Importation PDUFA- Prescription Drug User Fee Act HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-10-12T15:08:03.163000-04:00
2023003 POLITICAL CAPITAL, LLC f8e6f685-3258-429a-b9b3-0d1b2b09126c 3A POLITICAL CAPITAL, LLC 401104260 PINE PHARMACEUTICALS 2017 third_quarter PHA Outsourcing Facilities HR-2871 HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-10-12T15:46:08.543000-04:00
2023250 MCDERMOTT+ LLC 2bdd2d99-94b2-40fc-8017-bab0ba8197e2 Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2017 third_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-10-13T09:35:00.297000-04:00
2023621 MERCURY PUBLIC AFFAIRS, LLC 40e9e86b-cfec-47f9-8e82-b9351cccbe27 Q3 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2017 third_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2017-10-13T14:00:39.947000-04:00
2023677 MERCURY PUBLIC AFFAIRS, LLC 8e8e0ed9-4545-4855-9442-6b0f9fce5e06 Q3 MERCURY PUBLIC AFFAIRS, LLC 70175 MORRIS AND DICKSON 2017 third_quarter PHA IT Help RE Improper Prescriptions Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) 20000   0 0 2017-10-13T14:28:19.877000-04:00
2023786 FORGE FEDERAL AFFAIRS LLC 383cb981-286f-433e-bfc6-82abf342602f Q3 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2017 third_quarter PHA Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. P.L.115-52, FDA Reauthorization Act of 2017. HOUSE OF REPRESENTATIVES 20000   0 0 2017-10-13T15:08:26.677000-04:00
2023789 ACADEMY OF MANAGED CARE PHARMACY 70f65bde-06ef-4f03-acc4-ebeef51b20b8 Q3 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2017 third_quarter PHA Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2017-10-13T15:08:28.210000-04:00
2024134 BROYDRICK & ASSOCIATES c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82 Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2017 third_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-10-15T16:07:27.727000-04:00
2024317 NOVO NORDISK INC. 6aaa857e-0e24-4b29-beda-0cd42e6fdc79 Q3 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2017 third_quarter PHA Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; issues related to 340B program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE   790000 0 0 2017-10-16T10:09:53.430000-04:00
2024431 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 5154bb88-8f34-44da-82ef-3c0947001eee Q3 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2017 third_quarter PHA Oppose Rep. Carter's DIR Letter Oppose H.R 218: King Cove Road Land Exchange Act HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2017-10-16T10:47:57.780000-04:00
2024488 AKIN GUMP STRAUSS HAUER & FELD 5222be7d-8ffa-4c37-a765-637003c87daf Q3 AKIN GUMP STRAUSS HAUER & FELD 682 PHARMEDIUM SERVICES, LLC 2017 third_quarter PHA Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-10-16T10:57:33.780000-04:00
2024557 DAVE KOLBE CONSULTING 7a8c5238-9c5f-439d-855a-e7dabad9bacf Q3 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2017 third_quarter PHA Medicare Part-D rebates Trade agreements Patent reform issues Prescription Drug User Fee Act (PDUFA) HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-16T11:19:38.703000-04:00
2024592 AMERICAN CONSERVATIVE UNION f4b97c11-d2c8-4f07-8486-273b2e5f4032 Q3 AMERICAN CONSERVATIVE UNION 62712 AMERICAN CONSERVATIVE UNION 2017 third_quarter PHA S.974 - CREATES Act of 2017 H.R.2212 - CREATES Act of 2017 Federal Communications Commission (FCC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),SENATE,White House Office   10000 0 0 2017-10-16T11:31:13.690000-04:00
2024620 MANATT, PHELPS, AND PHILLIPS 7fe789a1-e887-463e-ae81-395ff0295349 Q3 MANATT, PHELPS, AND PHILLIPS 23645 NEKTAR THERAPEUTICS 2017 third_quarter PHA FDA oversight of certain pain reliever products Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-10-16T11:34:24.440000-04:00
2025087 HANCE SCARBOROUGH da2d86be-1ca2-4267-a1e3-693c09190f8a Q3 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2017 third_quarter PHA Issues related to the regulation of pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-16T14:08:08.480000-04:00
2025497 WINNING STRATEGIES WASHINGTON f7d6f86b-4e75-489c-93eb-b788ce3dc79e Q3 WINNING STRATEGIES WASHINGTON 50796 KALEO 2017 third_quarter PHA Pharmaceutical drug development including epinephrine for anaphylaxis Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE 30000   0 0 2017-10-16T14:57:04.083000-04:00
2025533 PENN AVENUE PARTNERS 686e540d-c981-4fad-929a-af1d6f01d892 Q3 PENN AVENUE PARTNERS 400918672 PURDUE PHARMA L.P. 2017 third_quarter PHA Monitoring legislative and regulatory activities impacting the pharmaceutical industry. SENATE 60000   0 0 2017-10-16T15:02:32.100000-04:00
2025651 ANIMAL HEALTH INSTITUTE 27651a7b-1601-4acb-bce3-c190666f447d Q3 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2017 third_quarter PHA Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products. Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   35000 0 0 2017-10-16T15:28:39.930000-04:00
2025783 FORBES-TATE 7cd416c6-e379-447b-b4d5-09d1c695829d Q3 FORBES-TATE 400976792 PHRMA 2017 third_quarter PHA Issues pertaining to Rx Drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-10-16T16:03:57.480000-04:00
2026206 WAXMAN STRATEGIES 7b334589-2757-4ea5-8194-3a0e82f15eb4 Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2017 third_quarter PHA Issues affecting the 340B drug pricing program HOUSE OF REPRESENTATIVES 18750   0 0 2017-10-17T09:12:29.677000-04:00
2026677 THE INGRAM GROUP LLC 17b6d6a8-bb39-4e35-8163-117e505a66c9 Q3 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2017 third_quarter PHA General issues related to the biopharmaceutical and pharmaceutical industries including drug importation. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-10-17T11:19:31.803000-04:00
2026860 AVENUE SOLUTIONS 24dfea5f-8918-464e-910f-2b1d83b8bdab Q3 AVENUE SOLUTIONS 72111 JAZZ PHARMACEUTICALS, INC. 2017 third_quarter PHA H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act of 2017); H.R. 2051, FAST Generics Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-17T12:09:22.950000-04:00
2027122 AVENUE SOLUTIONS f051bbe4-eeeb-4be7-8625-78a3afe3a503 Q3 AVENUE SOLUTIONS 72111 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 2017 third_quarter PHA Issues related to biosimilars   80000   0 0 2017-10-17T13:17:14.927000-04:00
2027144 AVENUE SOLUTIONS cb256bbd-4122-480d-ae92-8322b2494809 Q3 AVENUE SOLUTIONS 72111 MOMENTA PHARMACEUTICALS, INC. 2017 third_quarter PHA Improving access to biogenerics   50000   0 0 2017-10-17T13:22:30.817000-04:00
2027172 SQUIRE PATTON BOGGS 35e46449-2d1a-4c62-af4b-d73fd7fc4407 Q3 SQUIRE PATTON BOGGS 30906 BIOTECHNOLOGY INNOVATION ORGANIZATION 2017 third_quarter PHA Monitoring legislation that could impact pharmaceutical industry. Agriculture, Dept of (USDA),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2017-10-17T13:29:52.473000-04:00
2027208 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 55a5ade0-8186-4f9f-a374-46d05436fd84 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2017 third_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2017-10-17T13:35:10.350000-04:00
2027231 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 2a84c594-b784-4943-8bc2-55f056ffd52f Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2017 third_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2017-10-17T13:36:14.210000-04:00
2027244 SORINI, SAMET & ASSOCIATES, LLC dcaf6adc-5738-4e0a-8fd1-42af38536ad2 Q3 SORINI, SAMET & ASSOCIATES, LLC 317754 PETSMART, INC. 2017 third_quarter PHA Veterinary prescriptions Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,Intl Trade Administration (ITA),SENATE,U.S. International Trade Commission (ITC) 20000   0 0 2017-10-17T13:40:23.537000-04:00
2027249 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ba5a919f-80ec-4165-8b60-9ed9add90b7a Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2017 third_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2017-10-17T13:40:24.837000-04:00
2027304 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. e1f630f5-91e5-4903-90de-ea11b761385e Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2017 third_quarter PHA Issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-17T13:51:55.210000-04:00
2027786 PD FRAZER CONSULTING, INC. e62d3f0a-f34d-429d-82fa-bed56f8fe42e Q3 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2017 third_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-10-17T15:40:58.270000-04:00
2027836 PUBLIC CITIZEN b2e7ff17-ad83-4309-823d-51ce6ec5e573 Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2017 third_quarter PHA S 934/HR 2430-FDA re-authorization Act of 2017, S 974/HR 2212-CREATES Act, S 771/HR 1776-Improving access to affordable prescription drugs act, S 204-Trickett Wendler Right to try act of 2017, S 1509/HR 1223-OPEN act, S 1369/HR 2974-Stop Price Gouging Act, Preserve access to affordable generics act, HR 205-to amend the Food, Drug & Cosmetic Act to require labeling of genetically engineered fish, S 495-Medicaid Innovation Price Fund Act, S 252-Medicaid Drug Savings Act of 2017,S 1131/HR 2439-Fair Accountability and Innovative Research Drug Pricing Act of 2017, HR 1628-American Health Care Act of 2017, S 297-Increasing Competition in Pharmaceuticals Act, HR 749 Lower drugs through Competition act, S 1390-stronger patents act of 2017, S 168/HR 3536-A bill to require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements with Secretary of HHS. Consumer Product Safety Commission (CPSC),Federal Communications Commission (FCC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   70000 0 0 2017-10-17T15:46:23.960000-04:00
2028435 CONNECT 4 STRATEGIES, LLC b461cb9b-bb1a-433f-83ae-dde5e55ec9f4 Q3 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2017 third_quarter PHA s916 Access to Emergency Medications Act SENATE 20000   0 0 2017-10-17T20:04:30.357000-04:00
2028482 CHATMAN, LLC 33e2dd2d-cbda-4607-b4ce-e9d8bfb042f3 Q3 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2017 third_quarter PHA Support continuation of Pharmacy 340B program in HRSA. Provide comments to FDA proposed rule change. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-10-17T22:34:07.140000-04:00
2028532 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 76dfdf4d-781c-4c48-a4e9-74c5a26ad22e Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 third_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   176000 0 0 2017-10-18T08:58:59.663000-04:00
2028941 CORNERSTONE GOVERNMENT AFFAIRS, INC. 629f73e5-feb9-436d-99de-1d9103134c5e Q3 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2017 third_quarter PHA Representation on health-related issues including reimbursement, research, public-health & clinical care Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2017-10-18T10:30:12.283000-04:00
2029470 BLUECROSS BLUESHIELD OF TENNESSEE dab2ed1d-7357-4735-acf4-3b8d53803ce2 Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2017 third_quarter PHA General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2017-10-18T11:49:33.347000-04:00
2029638 ROCK & ASSOCIATES 125d504c-ffd5-402b-9afb-f5b773c0f028 Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:29:15.123000-04:00
2029641 ROCK & ASSOCIATES 574a0d61-84f1-4ab3-87a0-34c8aaf9b702 Q3 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:30:16.357000-04:00
2029647 ROCK & ASSOCIATES e7093e79-2bb6-450c-8d09-4e59b35bc28f Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:31:22.843000-04:00
2029651 WELLINGTON STRATEGIES, LLC. f6e211fc-fe9c-4147-ae83-18b412da86ca 3T WELLINGTON STRATEGIES, LLC. 401104410 OMNICELL, INC. 2017 third_quarter PHA Regulations pertaining to the Drug Quality and Security Act (Public Law No: 113-54) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 15000   0 1 2017-10-18T12:33:25.453000-04:00
2029653 ROCK & ASSOCIATES e23ea653-3c67-42fa-8aff-0507a17702ac Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:33:26.857000-04:00
2029659 ROCK & ASSOCIATES 7f912400-10ab-4d24-ab34-d85dd5cabdbf Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:36:32.360000-04:00
2029663 ROCK & ASSOCIATES bb9bccc6-76a2-4a1f-ac2d-aa950cab4212 Q3 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:37:33.843000-04:00
2029667 ROCK & ASSOCIATES a16b4722-d83e-4446-830d-098db682f9c7 Q3 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2017 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-10-18T12:38:37.797000-04:00
2029713 OREGON HEALTH & SCIENCE UNIVERSITY 91609100-a51d-4291-af2f-bb96763730d8 Q3 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2017 third_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2017-10-18T12:58:05.970000-04:00
2029893 THERMO FISHER SCIENTIFIC INC. 15bbfbdd-361f-49cc-939a-f966dd26c91a Q3 THERMO FISHER SCIENTIFIC INC. 323251 THERMO FISHER SCIENTIFIC INC 2017 third_quarter PHA Drug shortage prevention Abuse-deterrent pseudophedrine Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),SENATE   310000 0 0 2017-10-18T13:50:39.320000-04:00
2029919 AMERICAN PHARMACISTS ASSOCIATION da444c66-a1ba-4fd8-8436-16df0ca32260 Q3 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2017 third_quarter PHA HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2430 FDA Reauthorization Act of 2017 HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importati… HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2017-10-18T13:56:53.603000-04:00
2029956 NATIONAL NURSES UNITED d53b0622-f436-4c6f-89c3-45a13eb0829c Q3 NATIONAL NURSES UNITED 40021153 NATIONAL NURSES UNITED 2017 third_quarter PHA H.R. 1245 - support for Affordable & Safe Prescription Drug Importation Act H.R. 1776 - support for Improving Access to Affordable Prescription Drugs Act S. 469 - support for Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2017-10-18T14:04:13.417000-04:00
2030005 ACG ADVOCACY 0325964b-2fdc-4b87-9407-8be82b22bc77 Q3 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2017 third_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-10-18T14:08:35.370000-04:00
2030010 MWW GROUP ec82dd64-fa73-403c-b668-a5abdcf9bc1d Q3 MWW GROUP 26318 UNITED PHARMACY PARTNERS, INC. (UPPI) 2017 third_quarter PHA Nuclear pharmacy reimbursement; Conversion to Low Enriched Uranium (LEU)   10000   0 0 2017-10-18T14:09:38.713000-04:00
2030017 ACG ADVOCACY eac501fa-e1a9-48b2-8218-271b1e4a5be3 Q3 ACG ADVOCACY 2057 ROIVANT SCIENCES, INC. 2017 third_quarter PHA Drug Pricing. Innovation Issues. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-10-18T14:10:42.247000-04:00
2030177 KOUNTOUPES DENHAM CARR & REID, LLC 9f035a32-82a1-445f-a61c-2dbeba728b8f Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 third_quarter PHA General issues related to over the counter pharmaceuticals, cosmetics issues related to Rx/OTC transition issues related to draft legislation addressing the over the counter drug monograph process, and H. R. 2430, the FDA Reauthorization Act (FDARA) of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-10-18T14:41:17.140000-04:00
2030183 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 5e00fc37-1148-420a-b6b5-0bef0195d617 Q3 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2017 third_quarter PHA Proposals relating to the regulation of direct-to-consumer prescription drug advertising Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of   420000 0 0 2017-10-18T14:42:24.187000-04:00
2030438 KOUNTOUPES DENHAM CARR & REID, LLC 30383b92-2009-4d0f-92dc-8c251174d2bc Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2017 third_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Issues related to drug pricing such as S.771 and H.R. 1776, The Improving Access to Affordable Drugs Act. Issues related to opioid abuse. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-10-18T15:04:52.173000-04:00
2031304 KOUNTOUPES DENHAM CARR & REID, LLC 192b8d52-6451-42e3-b6b1-695a404e02e4 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2017 third_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including reauthorization of the Generic Drug User Fee Agreement, reauthorization of the Biosimilar User Fee Agreement, H.R. 2051, The FAST Generic Act of 2017, S.771 and H.R. 1776, Improving Access to Affordable Drugs, and changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Issues related to drug takeback and opioid addition. Issues realted to H. R. 2212 and S. 974, CREATES Act of 2017. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2017-10-18T17:38:30.503000-04:00
2031349 UNIVERSITY OF IOWA c942868e-aa79-4f10-8b08-06acd0331d1e Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2017 third_quarter PHA FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)   86662 0 0 2017-10-18T17:58:54.163000-04:00
2031412 ISEMAN & ASSOCIATES LLC 0f5cf7aa-0a3c-4605-8dc9-644519fc3a02 Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2017 third_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-10-18T18:14:20.273000-04:00
2031552 WEST FRONT STRATEGIES LLC fd18ef04-2430-4956-baa2-0e93f58e1b3a Q3 WEST FRONT STRATEGIES LLC 401103493 WALGREEN CO. 2017 third_quarter PHA Pharmacy and Medically Underserved Areas Enhancement Act (S. 109 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-10-18T20:44:36.227000-04:00
2031964 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3dd1df4a-6dfb-4ad7-8ef9-2376199860c6 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2017 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   115000 0 0 2017-10-19T09:30:37.763000-04:00
2032095 APOTEX CORP. ce5fc93c-8e31-4a48-b482-c888e9c6fef4 Q3 APOTEX CORP. 310973 APOTEX CORP. 2017 third_quarter PHA HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; and HR 2212/S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, and HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2017-10-19T09:46:26.920000-04:00
2032156 ELI LILLY AND COMPANY 3e090c12-29e6-43b4-b4b3-4a4982d18b80 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2017 third_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2020000 0 0 2017-10-19T09:52:52.390000-04:00
2032451 POWERS PYLES SUTTER & VERVILLE, P.C. 87bd9691-3b78-446e-8480-5a34215320c9 Q3 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 340B HEALTH 2017 third_quarter PHA Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills. HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2017-10-19T10:32:21.270000-04:00
2032527 AMERICAN VETERINARY MEDICAL ASSOCIATION 71a583dd-cfd2-4f49-9d5a-b18f30aed21a Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2017 third_quarter PHA H.R. 623 Fairness to Pet Owners Act Veterinary Compounding Draft Legislation Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   230000 0 0 2017-10-19T10:38:04.240000-04:00
2032560 AMERICAN VETERINARY MEDICAL ASSOCIATION 3fb06de5-92f2-494d-9845-b0d4698ba6ab Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2017 third_quarter PHA H.R. 623 Fairness to Pet Owners Act Veterinary Compounding Draft Legislation Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   230000 0 0 2017-10-19T10:39:15.520000-04:00
2032727 BUCHANAN INGERSOLL & ROONEY PC cb735764-282e-4ca1-8cf8-806cccd534d7 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 60 DEGREES PHARMACEUTICALS 2017 third_quarter PHA Government relations services relating to priority review voucher within the user fee reauthorization legislation (S.934/HR2430). HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-10-19T10:55:47.023000-04:00
2032770 GREATER NEW YORK HOSPITAL ASSOCIATION c5b8d8ac-1644-4fe0-b333-1abbda2589ab Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2017 third_quarter PHA Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297). Oppose legislation that would harm the 340B drug discount program for safety net hospitals. Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214) Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   600000 0 0 2017-10-19T11:01:10.100000-04:00
2032785 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS f43ce5e2-d6b8-48ee-9b46-f0c00968b8ec 3A AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2017 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   130000 0 0 2017-10-19T11:02:15.820000-04:00
2032961 CROSSROADS STRATEGIES, LLC e1082b4f-784b-4e96-b3d6-3bcdac0d8a71 Q3 CROSSROADS STRATEGIES, LLC 400531586 ALITHEON, INC. 2017 third_quarter PHA Issues related to the elimination of counterfeit pharmaceuticals. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Agency for International Development (USAID) 30000   0 0 2017-10-19T11:23:05.040000-04:00
2033151 BUCHANAN INGERSOLL & ROONEY PC 47834e65-e339-43eb-b02c-3f1a36b4f5b0 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 TONIX PHARMACEUTICALS HOLDING CORP. 2017 third_quarter PHA Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-10-19T11:46:00.170000-04:00
2033217 PRIME THERAPEUTICS b51fd801-10b3-45cf-ab29-a87134ec572b Q3 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2017 third_quarter PHA H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only). HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2017-10-19T11:51:35.547000-04:00
2033322 BUCHANAN INGERSOLL & ROONEY PC 2a81af43-baa1-4e60-a040-1e1c4290fb48 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 WOMEN'S CHOICE PHARMACEUTICALS, LLC 2017 third_quarter PHA Development of government relations strategy relating to prenatal dietary supplements. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-19T12:00:39.310000-04:00
2033535 KING & SPALDING LLP 47a8e406-a03d-4b10-85f6-ef19ce2c8a5d Q3 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2017 third_quarter PHA Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-10-19T12:20:27.500000-04:00
2033673 BARNES & THORNBURG, LLP 57f86381-8fac-49d6-afe8-7a433501cc4c 3T BARNES & THORNBURG, LLP 5404 CVS HEALTH 2017 third_quarter PHA Regulations affecting chain drug stores, pharmacy benefit managers and tax issues. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S. 50000   0 1 2017-10-19T12:37:50.707000-04:00
2034077 MASSACHUSETTS MEDICAL SOCIETY 45afe3ee-8ed1-4428-9455-27412e62ddf6 Q3 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2017 third_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2017-10-19T13:11:13.523000-04:00
2034308 BALLARD PARTNERS f595d4b6-5648-41ff-8e1a-2a8dd7be8f9b Q3 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2017 third_quarter PHA The registrant will advise and advocate for the client on general government policies and regulations. Health & Human Services, Dept of (HHS),White House Office 40000   0 0 2017-10-19T13:32:29.387000-04:00
2034353 SC PARTNERS LLC 7508cc30-d7dd-4da7-904e-a3b39532e06f Q3 SC PARTNERS LLC 318994 PFIZER, INC. 2017 third_quarter PHA Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. Affordable and Safe Prescription Drug Importation Act (S. 469) HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-10-19T13:36:59.480000-04:00
2034443 BLUE CROSS AND BLUE SHIELD ASSOCIATION f1c6be0c-94da-4c7e-884f-0be5c72b12b2 Q3 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2017 third_quarter PHA Drug Pricing; Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Vice President of the U.S.,White House Office   2040000 0 0 2017-10-19T13:41:38.277000-04:00
2034537 FARRAGUT PARTNERS LLP 99c61f61-e600-4cd8-86f0-976449fbc356 Q3 FARRAGUT PARTNERS LLP 401103938 AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS 2017 third_quarter PHA Issues pertaining to Prescription Drug Monitoring programs. Public Health. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-10-19T13:49:27.480000-04:00
2034563 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION fd18181b-5694-4b49-be92-8285b8d11af0 Q3 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2017 third_quarter PHA Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   746720 0 0 2017-10-19T13:50:39.637000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2351.435ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API